Home > Insider Trading > Filing (0001140361-18-005596)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1322505	Albireo Pharma Inc.	ALBO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1600023	Ltd Partners Phase4	1 Cavendish Place London X0 W1G 0QF	No	No	No	No
1687344	Phase4 Ventures Iii Lp	1 Cavendish Place London X0 W1G 0QF	No	No	No	No
1687418	Ltd Partner General Iii Ventures Phase4	50 Lothian Road, Festival Square Edinburgh X0 EH3 9WJ	No	No	No	No
1687429	Phase4 Ventures Iii Gp Lp	50 Lothian Road, Festival Square Edinburgh X0 EH3 9WJ	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-01-30	98,500	$34.40	1,066,947	No	4	S	Indirect	Held by Phase4 Ventures III GP LP
Common Stock	Disposition	2018-01-30	1,500	$37.06	1,065,447	No	4	S	Indirect	Held by Phase4 Ventures III GP LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	Held by Phase4 Ventures III GP LP
No	4	S	Indirect	Held by Phase4 Ventures III GP LP

Footnotes

The number of securities reported represents an aggregate number of shares sold in multiple market transactions over a range of sale prices. The Reporting Persons undertake to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Persons at each separate price within the range.
Sale prices range from $34.40 to $34.71, inclusive.
Sale prices range from $36.60 to $37.43, inclusive.
Consists of shares held by Phase4 Ventures III GP LP ("Phase4 GPLP") in its capacity as general partner of Phase4 Ventures III LP ("Phase4 III"). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase 4 Ventures III General Partner Limited ("Phase4 GP"). Phase4 GP has appointed Phase4 Partners Limited ("Phase4 Partners") to act as the manager of Phase4 III. Dr. Alastair McKinnon, Denise Scots-Knight, PhD, and Charles Sermon are Directors of Phase4 Partners (the "Phase4 Directors"). Each of the Phase4 Directors, Phase4 Partners, Phase4 GP, Phase 4 GPLP and Phase4 III may be deemed to beneficially own the shares held by Phase4 GPLP in its capacity as general partner of Phase4 III, but disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.